Detailed information for compound 187558
Basic information
Technical information
- TDR Targets ID: 187558
- Name: benzyl N-[(2S)-1-[[2-[(2-cyano-2-phenylethyl) amino]-2-oxoethyl]-[(4-phenylmethoxyphenyl)me thyl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan- 2-yl]carbamate
- MW: 670.756 | Formula: C39H38N6O5
-
H donors: 3
H acceptors: 5
LogP: 4.82
Rotable bonds: 20
Rule of 5 violations (Lipinski): 2 - SMILES: N#CC(c1ccccc1)CNC(=O)CN(C(=O)[C@H](Cc1nc[nH]c1)NC(=O)OCc1ccccc1)Cc1ccc(cc1)OCc1ccccc1
- InChi: 1S/C39H38N6O5/c40-21-33(32-14-8-3-9-15-32)22-42-37(46)25-45(24-29-16-18-35(19-17-29)49-26-30-10-4-1-5-11-30)38(47)36(20-34-23-41-28-43-34)44-39(48)50-27-31-12-6-2-7-13-31/h1-19,23,28,33,36H,20,22,24-27H2,(H,41,43)(H,42,46)(H,44,48)/t33?,36-/m0/s1
- InChiKey: SMBHALUVUUYXQI-CRGCAJGSSA-N
Network
Hover on a compound node to display the structore
Synonyms
- benzyl N-[(1S)-2-[(4-benzyloxyphenyl)methyl-[2-[(2-cyano-2-phenyl-ethyl)amino]-2-oxo-ethyl]amino]-1-(1H-imidazol-5-ylmethyl)-2-oxo-ethyl]carbamate
- N-[(1S)-2-[(4-benzyloxyphenyl)methyl-[2-[(2-cyano-2-phenylethyl)amino]-2-oxoethyl]amino]-1-(1H-imidazol-5-ylmethyl)-2-oxoethyl]carbamic acid benzyl ester
- phenylmethyl N-[(2S)-1-[[2-[(2-cyano-2-phenyl-ethyl)amino]-2-oxo-ethyl]-[(4-phenylmethoxyphenyl)methyl]amino]-3-(1H-imidazol-5-yl)-1-oxo-propan-2-yl]carbamate
- N-[(1S)-2-[(4-benzoxybenzyl)-[2-[(2-cyano-2-phenyl-ethyl)amino]-2-keto-ethyl]amino]-1-(1H-imidazol-5-ylmethyl)-2-keto-ethyl]carbamic acid benzyl ester
- phenylmethyl N-[(2S)-1-[[2-[(2-cyano-2-phenylethyl)amino]-2-oxoethyl]-[[4-(phenylmethoxy)phenyl]methyl]amino]-3-(3H-imidazol-4-yl)-1-oxopropan-2-yl]carbamate
- phenylmethyl N-[(1S)-2-[[2-[(2-cyano-2-phenyl-ethyl)amino]-2-oxo-ethyl]-[[4-(phenylmethoxy)phenyl]methyl]amino]-1-(3H-imidazol-4-ylmethyl)-2-oxo-ethyl]carbamate
- N-[(1S)-2-[[2-[(2-cyano-2-phenylethyl)amino]-2-oxoethyl]-[[4-(phenylmethoxy)phenyl]methyl]amino]-1-(3H-imidazol-4-ylmethyl)-2-oxoethyl]carbamic acid phenylmethyl ester
- N-[(1S)-2-[[4-(benzyloxy)benzyl]-[2-[(2-cyano-2-phenyl-ethyl)amino]-2-keto-ethyl]amino]-1-(3H-imidazol-4-ylmethyl)-2-keto-ethyl]carbamic acid benzyl ester
- phenylmethyl N-[(2S)-1-[[2-[(2-cyano-2-phenyl-ethyl)amino]-2-oxo-ethyl]-[[4-(phenylmethoxy)phenyl]methyl]amino]-3-(3H-imidazol-4-yl)-1-oxo-propan-2-yl]carbamate
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | Harvey rat sarcoma viral oncogene homolog | Starlite/ChEMBL | References |
| Rattus norvegicus | Protein farnesyltransferase | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
| Species | Potential target | Known druggable target | Length | Alignment span | Identity |
|---|---|---|---|---|---|
| Plasmodium falciparum | ras-related protein Rab-18 | Harvey rat sarcoma viral oncogene homolog | 189 aa | 177 aa | 25.4 % |
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Loa Loa (eye worm) | hypothetical protein | 0.0069 | 0.7974 | 1 |
| Schistosoma mansoni | protein farnesyltransferase subunit beta | 0.0067 | 0.7363 | 0.5 |
| Trypanosoma cruzi | lanosterol synthase, putative | 0.0074 | 1 | 1 |
| Trichomonas vaginalis | dexras1, putative | 0.0069 | 0.7974 | 1 |
| Plasmodium vivax | farnesyltransferase beta subunit, putative | 0.0067 | 0.7363 | 1 |
| Echinococcus multilocularis | ras gtpase | 0.0069 | 0.7974 | 1 |
| Entamoeba histolytica | Ras family GTPase | 0.0069 | 0.7974 | 1 |
| Trichomonas vaginalis | rheb, putative | 0.0069 | 0.7974 | 1 |
| Echinococcus granulosus | ras gtpase | 0.0069 | 0.7974 | 1 |
| Trypanosoma brucei | lanosterol synthase | 0.0074 | 1 | 1 |
| Giardia lamblia | Prenyltransferase | 0.0067 | 0.7363 | 0.5 |
| Loa Loa (eye worm) | Ras protein let-60 | 0.0069 | 0.7974 | 1 |
| Trichomonas vaginalis | ras-dva small GTPase, putative | 0.0069 | 0.7974 | 1 |
| Trichomonas vaginalis | GTP-binding protein rit, putative | 0.0069 | 0.7974 | 1 |
| Brugia malayi | Ras protein let-60 | 0.0069 | 0.7974 | 1 |
| Brugia malayi | Ras-related protein R-Ras2 | 0.0069 | 0.7974 | 1 |
| Leishmania major | farnesyltransferase beta subunit | 0.0067 | 0.7363 | 1 |
| Entamoeba histolytica | Ras family GTPase | 0.0069 | 0.7974 | 1 |
| Entamoeba histolytica | ras-1, putative | 0.0069 | 0.7974 | 1 |
| Toxoplasma gondii | prenyltransferase and squalene oxidase repeat-containing protein | 0.0067 | 0.7363 | 0.5 |
| Trypanosoma cruzi | lanosterol synthase, putative | 0.0074 | 1 | 1 |
| Trichomonas vaginalis | ral, putative | 0.0069 | 0.7974 | 1 |
| Trichomonas vaginalis | rap1 and, putative | 0.0069 | 0.7974 | 1 |
| Plasmodium falciparum | protein farnesyltransferase subunit beta | 0.0067 | 0.7363 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| IC50 (binding) | = 0.002 uM | In vitro inhibition of rat farnesyltransferase. | ChEMBL. | 9341905 |
| IC50 (binding) | = 0.002 uM | In vitro inhibition of rat farnesyltransferase. | ChEMBL. | 9341905 |
| IC50 (functional) | = 0.19 uM | Concentration required to inhibit 50% of the cultured colonies of H-Ras-Fcells . | ChEMBL. | 9341905 |
| IC50 (functional) | = 0.19 uM | Concentration required to inhibit 50% of the cultured colonies of H-Ras-Fcells . | ChEMBL. | 9341905 |
| MED (functional) | = 0.05 uM | Minimum effective dose required to detect unfarnesylated Ras in H-Ras-transformed NIH3T3 (H-Ras-F) cells injected into mice. | ChEMBL. | 9341905 |
| MED (functional) | = 0.05 uM | Minimum effective dose required to detect unfarnesylated Ras in H-Ras-transformed NIH3T3 (H-Ras-F) cells injected into mice. | ChEMBL. | 9341905 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL115943
- PubChem: 11802593
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.